Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanofi Sheds Light On Plans For LixiLan, U300 At ADA

This article was originally published in The Pink Sheet Daily

Executive Summary

Sanofi released positive data from two Phase III trials showing the next-generation insulin glargine U300 worked as well as Lantus in controlling blood sugar in patients with type 2 diabetes but with night-time benefits. The company also announced plans to initiate a Phase III trial studying a combination of the GLP-1 agonist Lyxumia with Lantus in the first half of 2014.


Related Content

Sanofi’s Toujeo Is Approved, Now The Hard Part: Commercialization
On The Wings Of Lantus: Sanofi Sees Clearer Skies Ahead In Diabetes


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts